THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Lucila Garcia-Contreras to Administration, Inhalation

This is a "connection" page, showing publications Lucila Garcia-Contreras has written about Administration, Inhalation.
  1. Mechanisms of absorption and elimination of drugs administered by inhalation. Ther Deliv. 2013 Aug; 4(8):1027-45.
    View in: PubMed
    Score: 0.440
  2. Pharmacokinetics and pharmacodynamics of high doses of inhaled dry powder drugs. Int J Pharm. 2018 Oct 05; 549(1-2):306-316.
    View in: PubMed
    Score: 0.156
  3. Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs. J Pharm Sci. 2017 01; 106(1):331-337.
    View in: PubMed
    Score: 0.138
  4. Inhaled Formulation Design for the Treatment of Lung Infections. Curr Pharm Des. 2015; 21(27):3875-901.
    View in: PubMed
    Score: 0.121
  5. Implications of increased nanoparticle absorption by infant lungs: future prospects. Ther Deliv. 2013 Apr; 4(4):417-20.
    View in: PubMed
    Score: 0.107
  6. Pharmaceutical aerosols for the treatment and prevention of tuberculosis. Front Cell Infect Microbiol. 2012; 2:118.
    View in: PubMed
    Score: 0.103
  7. Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs. Antimicrob Agents Chemother. 2012 May; 56(5):2612-8.
    View in: PubMed
    Score: 0.099
  8. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother. 2010 Apr; 54(4):1436-42.
    View in: PubMed
    Score: 0.086
  9. In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev. 2007 Sep 30; 59(11):1133-51.
    View in: PubMed
    Score: 0.073
  10. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 2007 Aug; 51(8):2830-6.
    View in: PubMed
    Score: 0.072
  11. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J Antimicrob Chemother. 2006 Nov; 58(5):980-6.
    View in: PubMed
    Score: 0.068
  12. Aerosol treatment of cystic fibrosis. Crit Rev Ther Drug Carrier Syst. 2003; 20(5):317-56.
    View in: PubMed
    Score: 0.053
  13. Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy. Adv Drug Deliv Rev. 2002 Dec 05; 54(11):1491-504.
    View in: PubMed
    Score: 0.053
  14. Immunological and toxicological implications of short-term studies in animals of pharmaceutical aerosol delivery to the lungs: relevance to humans. Crit Rev Ther Drug Carrier Syst. 2001; 18(4):387-431.
    View in: PubMed
    Score: 0.046
  15. Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J. 2010 Sep; 12(3):330-7.
    View in: PubMed
    Score: 0.022
  16. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob Agents Chemother. 2009 Apr; 53(4):1338-43.
    View in: PubMed
    Score: 0.020
  17. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm Res. 2008 Apr; 25(4):805-11.
    View in: PubMed
    Score: 0.018
  18. Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. Pharm Res. 2007 Oct; 24(10):1834-43.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES